» Articles » PMID: 32984773

Thrombospondins and Remodeling of the Tumor Microenvironment

Overview
Journal Vessel Plus
Date 2020 Sep 28
PMID 32984773
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular remodeling defines cancer growth and aggressiveness. Although cancer cells produce pro-angiogenic signals, the fate of angiogenesis critically depends on the cancer microenvironment. Composition of the extracellular matrix (ECM) and tumor inflammation determine whether a cancer will remain dormant, will be recognized by the immune system and eliminated, or whether the tumor will develop and lead to the spread and metastasis of cancer cells. Thrombospondins (TSPs), a family of ECM proteins that has long been associated with the regulation of angiogenesis and cancer, regulate multiple physiological processes that determine cancer growth and spreading, from angiogenesis to inflammation, metabolic changes, and properties of ECM. Here, we sought to review publications that describe various functions of TSPs that link these proteins to regulation of cancer growth by modulating multiple physiological and pathological events that prevent or support tumor development. In addition to its direct effects on angiogenesis, TSPs have important roles in regulation of inflammation, immunity, ECM properties and composition, and glucose and insulin metabolism. Furthermore, TSPs have distinct roles as regulators of remodeling in tissues and tumors, such that the pathways activated by a single TSP can interact and influence each other. The complex nature of TSP interactions and functions, including their different cell- and tissue-specific effects, may lead to confusing results and controversial conclusions when taken out of the context of interdisciplinary and holistic approaches. However, studies of TSP functions and roles in different systems of the organism offer an integrative view of tumor remodeling and a potential for finding therapeutic targets that would modulate multiple complementary processes associated with cancer growth.

Citing Articles

The Regulation of Exosome Generation and Function in Physiological and Pathological Processes.

Wang Y, Xiao T, Zhao C, Li G Int J Mol Sci. 2024; 25(1).

PMID: 38203424 PMC: 10779122. DOI: 10.3390/ijms25010255.


Pathophysiological roles of thrombospondin-4 in disease development.

Genaro K, Luo Z Semin Cell Dev Biol. 2023; 155(Pt B):66-73.

PMID: 37391348 PMC: 10753034. DOI: 10.1016/j.semcdb.2023.06.007.


Pterostilbene supresses inflammation-induced melanoma metastasis by impeding neutrophil elastase-mediated thrombospondin-1 degradation.

Su D, Xu S, Ji K, Xu H, Li Y, Zhang Z Chin Herb Med. 2023; 15(1):94-101.

PMID: 36875428 PMC: 9975619. DOI: 10.1016/j.chmed.2022.08.004.


Decellularized Colorectal Cancer Matrices as Bioactive Scaffolds for Studying Tumor-Stroma Interactions.

Marques-Magalhaes A, Cruz T, Costa A, Estevao D, Rios E, Canao P Cancers (Basel). 2022; 14(2).

PMID: 35053521 PMC: 8773780. DOI: 10.3390/cancers14020359.


The Role of the Innate Immune System in Cancer Dormancy and Relapse.

Chernosky N, Tamagno I Cancers (Basel). 2021; 13(22).

PMID: 34830776 PMC: 8615859. DOI: 10.3390/cancers13225621.


References
1.
Montane J, Cadavez L, Novials A . Stress and the inflammatory process: a major cause of pancreatic cell death in type 2 diabetes. Diabetes Metab Syndr Obes. 2014; 7:25-34. PMC: 3917922. DOI: 10.2147/DMSO.S37649. View

2.
Yap R, Veliceasa D, Emmenegger U, Kerbel R, McKay L, Henkin J . Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res. 2005; 11(18):6678-85. DOI: 10.1158/1078-0432.CCR-05-0621. View

3.
Ewald N, Kaufmann C, Raspe A, Kloer H, Bretzel R, Hardt P . Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2011; 28(4):338-42. DOI: 10.1002/dmrr.2260. View

4.
Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L . Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs. 2008; 27(4):304-18. PMC: 2701494. DOI: 10.1007/s10637-008-9175-7. View

5.
Krukovets I, Legerski M, Sul P, Stenina-Adognravi O . Inhibition of hyperglycemia-induced angiogenesis and breast cancer tumor growth by systemic injection of microRNA-467 antagonist. FASEB J. 2015; 29(9):3726-36. PMC: 4550367. DOI: 10.1096/fj.14-267799. View